{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:16:32Z","timestamp":1786119392700,"version":"build-2736575974"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1097\/gco.0b013e328334e44e","type":"journal-article","created":{"date-parts":[[2009,12,24]],"date-time":"2009-12-24T03:17:17Z","timestamp":1261624637000},"page":"56-60","source":"Crossref","is-referenced-by-count":32,"title":["Managing the toxicities of the aromatase inhibitors"],"prefix":"10.1097","volume":"22","author":[{"given":"Joanne E","family":"Mortimer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20210129","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1470-2045(07)70385-6","article-title":"Alone or in Combination (ATAC) Trialists Group Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.","volume":"9","author":"The Arimidex","year":"2008","journal-title":"Lancet Oncol"},{"key":"R2-11-20210129","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1056\/NEJMoa0810818","article-title":"I.G.C.G. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.","volume":"361","author":"The","year":"2009","journal-title":"N Engl J Med"},{"key":"R3-11-20210129","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0140-6736(07)60200-1","article-title":"Survival and safety of exemestane versus tamoxifen after 2-3 years tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.","volume":"369","author":"Coombes","year":"2007","journal-title":"Lancet"},{"key":"R4-11-20210129","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1200\/JCO.2005.00.6916","article-title":"Cutaneous adverse effects with HER1\/EGFR-targeted agents: Is there a silver lining?","volume":"23","author":"Perez-Soler","year":"2005","journal-title":"J Clin Oncol"},{"key":"R5-11-20210129","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10549-007-9612-x","article-title":"for the WHEL Study Group. Tamoxifen, hot flashes and recurrence in breast cancer","volume":"108","author":"Mortimer","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"R6-11-20210129","first-page":"2069","article-title":"Hot flushes and the risk of recurrence retrospective, exploratory results from the ATAC trial","volume":"106","author":"Cuzick","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"R7-11-20210129","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1200\/JCO.2003.07.071","article-title":"Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer","volume":"21","author":"Partridge","year":"2003","journal-title":"J Clin Oncol"},{"key":"R8-11-20210129","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.2007.11.5451","article-title":"Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer","volume":"26","author":"Partridge","year":"2008","journal-title":"J Clin Oncol"},{"key":"R9-11-20210129","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1200\/JCO.1995.13.11.2737","article-title":"Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy","volume":"13","author":"Couzi","year":"1995","journal-title":"J Clin Oncol"},{"key":"R10-11-20210129","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1200\/JCO.2002.20.6.1578","article-title":"Phase III evaluation of fluoxetine for treatment of hot flashes","volume":"20","author":"Loprinzi","year":"2002","journal-title":"J Clin Oncol"},{"key":"R11-11-20210129","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1200\/JCO.2008.19.6253","article-title":"Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis","volume":"27","author":"Loprinzi","year":"2009","journal-title":"J Clin Oncol"},{"key":"R12-11-20210129","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1001\/jama.289.21.2827","article-title":"Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial","volume":"289","author":"Stearns","year":"2003","journal-title":"JAMA"},{"key":"R13-11-20210129","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.clpt.2006.03.013","article-title":"Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment","volume":"80","author":"Borges","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"R14-11-20210129","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1200\/JCO.2006.07.5390","article-title":"Phase III trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressant alone: NCCTG N03C5","volume":"25","author":"Loprinzi","year":"2007","journal-title":"J Clin Oncol"},{"key":"R15-11-20210129","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa032312","article-title":"A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer","volume":"349","author":"Goss","year":"2003","journal-title":"N Engl J Med"},{"key":"R16-11-20210129","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S1470-2045(08)70182-7","article-title":"Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis","volume":"9","author":"Sestak","year":"2008","journal-title":"Lancet Oncol"},{"key":"R17-11-20210129","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1200\/JCO.2007.10.7573","article-title":"Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer","volume":"25","author":"Crew","year":"2007","journal-title":"J Clin Oncol"},{"key":"R18-11-20210129","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1002\/cncr.24419","article-title":"Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors","volume":"115","author":"Jun","year":"2009","journal-title":"Cancer"},{"key":"R19-11-20210129","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1200\/JCO.2007.15.4005","article-title":"Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome","volume":"26","author":"Morales","year":"2008","journal-title":"J Clin Oncol"},{"key":"R20-11-20210129","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3747\/co.2007.152","article-title":"Management of arthralgias associated with aromatase inhibitor therapy","volume":"14S","author":"Thorne","year":"2007","journal-title":"Curr Oncol Rep"},{"key":"R21-11-20210129","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1001\/jama.1925.02660280001001","article-title":"Arthritis of the menopause: a study of fifty cases","volume":"84","author":"Cecil","year":"1925","journal-title":"J Am Med Assoc"},{"key":"R22-11-20210129","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1002\/art.21364","article-title":"Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation","volume":"52","author":"Felson","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R24-11-20210129","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1200\/JCO.2008.19.6162","article-title":"High prevalence of vitamin D deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy","volume":"27","author":"Crew","year":"2009","journal-title":"J Clin Oncol"},{"key":"R25-11-20210129","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2217\/ahe.09.24","article-title":"Bone health maintenance in survivors of breast and prostate cancer","volume":"5","author":"Tagawa","year":"2009","journal-title":"Aging Health"},{"key":"R26-11-20210129","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","article-title":"American Society of Clinical Oncology 2003 Update on the role of bisphosphonates and bone health issues in women with breast cancer","volume":"21","author":"Hillner","year":"2003","journal-title":"J Clin Oncol"},{"key":"R27-11-20210129","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1200\/JCO.1999.17.5.1488","article-title":"Effect of tamoxifen on sexual functioning in patients with breast cancer","volume":"17","author":"Mortimer","year":"1999","journal-title":"J Clin Oncol"},{"key":"R28-11-20210129","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1200\/JCO.1999.17.9.2659","article-title":"Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 study","volume":"17","author":"Day","year":"1999","journal-title":"J Clin Oncol"},{"key":"R29-11-20210129","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.breast.2008.04.001","article-title":"The impact of aromatase inhibitors on sexual functioning: Current knowledge and future research directions","volume":"17","author":"Mok","year":"2008","journal-title":"Breast"},{"key":"R30-11-20210129","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1200\/JCO.1997.15.3.969","article-title":"Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer","volume":"15","author":"Loprinzi","year":"1997","journal-title":"J Clin Oncol"},{"key":"R31-11-20210129","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1093\/jnci\/92.13.1054","article-title":"Managing menopausal symptoms in breast cancer survivors: results of a randomized controlled trial","volume":"92","author":"Ganz","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"R33-11-20210129","doi-asserted-by":"crossref","first-page":"5715","DOI":"10.1200\/JCO.2007.12.1665","article-title":"Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial","volume":"25","author":"Mouridsen","year":"2007","journal-title":"J Clin Oncol"},{"key":"R34-11-20210129","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1001\/jama.285.11.1489","article-title":"Hormone replacement therapy and cognition: systematic review and meta-analysis","volume":"285","author":"LeBlanc","year":"2001","journal-title":"JAMA"},{"key":"R35-11-20210129","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1001\/jama.289.20.2651","article-title":"Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study: a Randomized Controlled Trial","volume":"289","author":"Shumaker","year":"2003","journal-title":"JAMA"},{"key":"R36-11-20210129","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1001\/jama.291.24.2947","article-title":"for the Women's Health Initiative Memory, S., Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study","volume":"291","author":"Shumaker","year":"2004","journal-title":"JAMA"},{"key":"R37-11-20210129","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1001\/jama.289.20.2663","article-title":"Effect of estrogen plus progestin on global cognitive function in postmenopausal women: The Women's Health Initiative Memory Study: a Randomized Controlled Trial","volume":"289","author":"Rapp","year":"2003","journal-title":"JAMA"},{"key":"R38-11-20210129","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/pon.709","article-title":"Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study","volume":"13","author":"Jenkins","year":"2004","journal-title":"Pscho-Oncology"},{"key":"R39-11-20210129","first-page":"S31","article-title":"A planned comparison of menopausal symptoms during year 1 in patients receiving either exemestane of tamoxifen in a double-blind adjuvant hormonal study","volume":"82","author":"Jones","year":"2003","journal-title":"Breast Cancer Res Treat"},{"key":"R40-11-20210129","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S1470-2045(08)70207-9","article-title":"Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II).","volume":"9","author":"Jenkins","year":"2008","journal-title":"Lancet Oncol"}],"container-title":["Current Opinion in Obstetrics & Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/GCO.0b013e328334e44e","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:12:27Z","timestamp":1786039947000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001703-201002000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/gco.0b013e328334e44e","relation":{},"ISSN":["1040-872X"],"issn-type":[{"value":"1040-872X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,2]]}}}